Dr. Francois Nader, President and CEO of NPS Pharmaceuticals, Inc. (NPSP), presented financial projections and plans to increase shareholder value at the 34th Annual Canaccord Genuity Global Growth Conference on Thursday.
Nader forecasted strong financial results from last year’s launch of Gattex/Revestive in second quarter 2013, which continues to deliver significant growth, with year-over-year 2014 growth on track for 200%-plus. This translates to guided gross sales projected between $100 and $110 million by 4Q2014, Nader said.
Nader also announced that the company will expand into its first international market when it begins promoting Gattex/Revestive in the U.K. The company is already working on additional expansion into France, Germany, the Nordics and Argentina, he said.
FOR THE LATEST TWST PHARMACEUTICALS REPORT CLICK HERE.
Nader also announced that the company is focused on advancing the regulatory process for Natpara, a novel drug on the verge of receiving FDA approval for the treatment of hypoparathyroidism, a rare multidimensional disorder that affects 180,000 people worldwide. He says of the approximately 50,000 patients in the U.S., 40% are uncontrolled with current management protocols, and this uncontrolled population will be the initial focus of the launch.
Finally, Nader said the company is tracking NPSP795, a potential new drug in development for Autosomal Dominant Hypocalcemia, a rare genetic disease caused by mutations of the calcium-sensing receptor gene affecting children and adults. There is no known cure, he said. The drug is currently in Phase II proof-of-concept study, he said.
According to Nader, these activities, combined with royalties from Amgen’s global sales of Sensipar, show a guided projection of net income of $54 million in 2Q2014.
FOR THE FULL PRESENTATION CLICK HERE.
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals (JAZZ), Presents at Canaccord Genuity Growth Conference
August 15, 2014
Matt Flake, President and CEO of Q2 Holdings Inc (QTWO), Presents at Canaccord Genuity Global Growth Conference
August 15, 2014
Yves J. Ribeill, President and CEO, Scynexis, Inc. (SCYX), Presents at Canaccord Genuity Growth Conference
August 18, 2014
Dr. Daniel Gold, President and CEO of MEI Pharma Inc (MEIP), Presents at Canaccord Genuity Growth Conference
August 19, 2014
Sanj K. Patel, President and CEO of Synageva BioPharma Corp. (GEVA), Presents at the Canaccord Genuity Growth
August 15, 2014
